Stiripentol gets TGA approval for Dravet syndrome


26 Sep 2019

Stiripentol (Diacomit) has been listed by the TGA for treatment of seizures in infants associated with Dravet syndrome.

The anticonvulsant has been added to the Australian Register of Therapeutic Goods for adjunctive treatment of generalised tonic-clonic and clonic seizures associated with severe myoclonic epilepsy in infancy in patients whose seizures are not adequately controlled with a benzodiazepine (usually clobazam) and valproate.

According to the TGA listing, stiripentol has an anti-epileptic action by potentiating GABA-ergic transmissions in CNS. Stiripentol also potentiates the effects (both wanted and unwanted)  of other anticonvulsants, as a result of the pharmacokinetic interactions. It may also cause sedation.

Until now the drug has not been available in Australia, but has been imported for use in some patients with Dravet syndrome. The drug’s sponsor is Emerge Health, Victoria.

Already a member?

Login to keep reading.

Email me a login link